Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.

ABSTRACT:

Aims

Reflecting both increased venous pressure and reduced cardiac output, abnormal liver tests are common in patients with severe heart failure and are associated with adverse clinical outcomes. We aimed to investigate the prognostic significance of abnormal liver tests in ambulatory patients with heart failure with reduced ejection fraction (HFrEF), explore any treatment interaction between bilirubin and sodium-glucose cotransporter 2 (SGLT2) inhibitors and examine change in liver tests with SGLT2 inhibitor treatment.

Methods and results

We explored these objectives in the Dapagliflozin And Prevention of Adverse outcomes in Heart Failure (DAPA-HF) trial, with focus on bilirubin. We calculated the incidence of cardiovascular death or worsening heart failure by bilirubin ter

SUBMITTER: Adamson C 

PROVIDER: S-EPMC9805158 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature